Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants

Čájet eará veršuvnnaid (1)

New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as well as interactions with other routine vaccines administered in infancy, we randomized health...

Bibliográfalaš dieđut
Váldodahkkit:	Ota, M, Odutola, A, Owiafe, P, Donkor, S, Owolabi, O, Brittain, N, Williams, N, Rowland-Jones, S, Hill, A, Adegbola, R, Mcshane, H
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2011

Geahča maid

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
Dahkki: Ota, M, et al.
Almmustuhtton: (2011)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
Dahkki: Odutola, A, et al.
Almmustuhtton: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
Dahkki: Odutola, A, et al.
Almmustuhtton: (2012)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
Dahkki: Brookes, R, et al.
Almmustuhtton: (2008)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
Dahkki: Roger H Brookes, et al.
Almmustuhtton: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
Dahkki: Roger H. Brookes, et al.
Almmustuhtton: (2011-01-01)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
Dahkki: Rowland, R, et al.
Almmustuhtton: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
Dahkki: Pathan, A, et al.
Almmustuhtton: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
Dahkki: Pathan, A, et al.
Almmustuhtton: (2012)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
Dahkki: Owiafe, P, et al.
Almmustuhtton: (2012)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
Dahkki: Ibanga, H, et al.
Almmustuhtton: (2006)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
Dahkki: Whelan, K, et al.
Almmustuhtton: (2009)

Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
Dahkki: Imoukhuede, E, et al.
Almmustuhtton: (2006)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
Dahkki: Harris, S, et al.
Almmustuhtton: (2011)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
Dahkki: Sander, C, et al.
Almmustuhtton: (2009)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
Dahkki: Meyer, J, et al.
Almmustuhtton: (2013)

Safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates: a randomized controlled trial
Dahkki: Mensah, V, et al.
Almmustuhtton: (2017)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
Dahkki: Meyer, J, et al.
Almmustuhtton: (2013)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
Dahkki: Hawkridge, T, et al.
Almmustuhtton: (2008)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
Dahkki: Kathryn T. Whelan, et al.
Almmustuhtton: (2011-01-01)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
Dahkki: Rowland, R, et al.
Almmustuhtton: (2013)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
Dahkki: Mcshane, H
Almmustuhtton: (2008)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
Dahkki: White, A, et al.
Almmustuhtton: (2013)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
Dahkki: Scriba, T, et al.
Almmustuhtton: (2011)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
Dahkki: Mcshane, H, et al.
Almmustuhtton: (2005)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
Almmustuhtton: (2011-01-01)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
Dahkki: Mcshane, H, et al.
Almmustuhtton: (2016)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
Dahkki: Minassian, A, et al.
Almmustuhtton: (2011)

Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.
Dahkki: Mullarkey, C, et al.
Almmustuhtton: (2013)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
Dahkki: Dieye, T, et al.
Almmustuhtton: (2013)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
Dahkki: Thomas, Z, et al.
Almmustuhtton: (2014)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.
Dahkki: de Cassan, S, et al.
Almmustuhtton: (2010)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
Dahkki: Fletcher, H, et al.
Almmustuhtton: (2008)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
Dahkki: Satti, I, et al.
Almmustuhtton: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
Dahkki: Satti, I, et al.
Almmustuhtton: (2014)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
Dahkki: Wajja, A, et al.
Almmustuhtton: (2017)

The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo.
Dahkki: Ota, M, et al.
Almmustuhtton: (2007)

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses
Dahkki: Antrobus, R, et al.
Almmustuhtton: (2014)

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.
Dahkki: Antrobus, R, et al.
Almmustuhtton: (2014)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
Dahkki: Anne Wajja, et al.
Almmustuhtton: (2017-05-01)